News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
Presentation AHA 2023 Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events Presenter: Jing Li November 16, 2023
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2020 No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk Michael O'Riordan November 19, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages Michael O'Riordan November 12, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2018 New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening Michael O'Riordan November 10, 2018
News Conference News AHA 2014 FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes November 16, 2014